Rare diseases
Investigational molecules
Locations
Generaal De Wittelaan L11 A3, 2800 Mechelen, Belgium
Galapagos focuses on relapsed or refractory blood cancers, with studies in multiple myeloma, chronic lymphocytic leukemia, small lymphocytic lymphoma, and B-cell non-Hodgkin lymphoma. The portfolio includes CAR T-cell therapy and anti-CD19 or anti-BCMA approaches aimed at difficult-to-treat malignant B-cell disorders.
These oncology programs span multiple active sites across several countries, reflecting a strong interest in advanced cellular immunotherapy for resistant haematologic disease.
Galapagos runs clinical trials in conditions such as Chronic lymphocytic leukaemia, B-cell small lymphocytic lymphoma, Systemic lupus erythematosus, Plasma cell myeloma refractory, among others.
Clinical trials run by this sponsor – those enrolling participants first.
Belgium
BulgariaBelgiumBelgiumBelgiumBelgiumBelgiumIncrease visibility for your trials and help patients find your site through our platform.
Tell us about your condition – we search every trial in Europe and connect you with the right site.
